Karyopharm Therapeutics Ratios (2012-2025) | KPTI

1Y3Y5Y7Y10YAll
Download Data
Ratios Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Profitability
Gross Margin (Quarter)
94.96%98.44%99.41%97.01%97.63%97.29%94.44%96.51%96.82%97.47%96.69%94.39%96.72%96.81%96.39%95.82%97.32%95.27%95.31%
EBT Margin (Quarter)
-246.20%-236.49%-137.19%54.37%-86.57%-123.34%-100.37%-114.45%-88.05%-86.49%-95.79%300.22%-112.57%55.76%-82.62%-101.40%-78.05%-98.11%-75.14%264.44%
EBIT Margin (Quarter)
-225.16%-217.02%-116.25%37.19%-72.55%-108.14%-85.32%-100.86%-79.85%-78.70%-86.81%-112.03%-101.91%-65.72%-67.77%-102.42%-110.80%-64.30%-34.56%93.03%
EBITDA Margin (Quarter)
-225.16%-217.02%-116.25%37.19%-72.55%-108.14%-85.32%-100.86%-79.85%-78.70%-86.81%-112.03%-101.91%-65.72%-67.77%-102.42%-110.80%-64.30%-34.56%93.03%
Operating Margin (Quarter)
-225.16%-217.02%-116.25%37.19%-72.55%-108.14%-85.32%-100.86%-79.85%-78.70%-86.81%-112.03%-101.91%-65.72%-67.77%-102.42%-110.80%-64.30%-34.56%93.03%
Net Margin (Quarter)
-246.84%-237.08%-137.47%54.44%-86.84%-123.65%-100.50%-114.76%-88.19%-86.83%-95.83%299.84%-112.79%55.61%-82.70%-101.04%-78.17%-98.22%-75.21%264.64%
FCF Margin (Quarter)
-227.38%-246.66%-63.57%20.01%-124.35%-88.57%-78.60%-79.94%-48.87%-68.38%-82.01%-55.07%-132.58%-89.98%-50.16%-84.33%-129.88%-49.29%-13.30%-34.71%
Efficiency
Inventory Average (Quarter)
2.88M3.51M3.92M4.02M3.99M3.67M3.86M4.24M4.03M3.75M3.39M3.07M2.91M3.12M4.07M4.71M4.75M4.88M4.48M4.00M
Assets Average (Quarter)
293.98M280.74M270.33M279.70M299.67M275.26M243.86M294.70M341.99M311.81M283.89M255.20M222.45M209.22M201.73M176.95M146.06M116.30M100.56M102.32M
Equity Average (Quarter)
5.45M-61.39M-104.55M-102.83M-81.38M-99.71M-128.31M-78.47M-30.91M-58.21M-85.82M-118.30M-152.58M-150.55M-145.89M-172.83M-195.95M-222.41M-254.09M-281.09M
Invested Capital (Quarter)
-39.64M-83.13M-125.98M-79.67M-83.08M-116.34M-140.28M-16.66M-45.17M-71.25M-100.40M-136.21M-168.96M-132.14M-159.65M-186.02M-205.88M-232.68M-256.76M-271.92M
Asset Utilization Ratio (Quarter)
0.390.360.440.750.780.911.020.530.430.470.510.570.630.700.740.820.971.181.421.43
Leverage & Solvency
Interest Coverage Ratio (Quarter)
-10.28-9.81-5.475.91-5.17-6.80-5.04-5.76-5.37-5.11-5.15-6.09-5.74-3.14-2.31-2.79-3.02-2.17-1.382.51
Debt to Equity (Quarter)
-0.71-0.59-0.51-0.46-0.40-0.36-0.40
Debt Ratio (Quarter)
0.440.500.580.750.911.001.07
Equity Ratio (Quarter)
-0.14-0.29-0.50-0.26-0.28-0.45-0.61-0.05-0.14-0.24-0.37-0.57-0.83-0.62-0.84-1.13-1.61-2.28-2.80-2.70
Times Interest Earned (Quarter)
-10.28-9.81-5.475.91-5.17-6.80-5.04-5.76-5.37-5.11-5.15-6.09-5.74-3.14-2.31-2.79-3.02-2.17-1.382.51
Valuation
Enterprise Value (Quarter)
-136.71M-235.89M-204.21M-44.51M-53.07M-170.85M-148.38M-143.84M-260.38M-156.44M-165.21M-191.44M-148.58M-152.12M-133.53M-108.71M-69.94M-47.88M-43.55M-50.94M
Return Ratios
Return on Sales (Quarter)
-2.47%-2.37%-1.37%0.54%-0.87%-1.24%-1.00%-1.15%-0.88%-0.87%-0.96%3.00%-1.13%0.56%-0.83%-1.01%-0.78%-0.98%-0.75%2.65%
Return on Capital Employed (Quarter)
-0.76%-0.83%-0.90%-0.48%-0.34%-0.35%-0.34%-0.62%-0.49%-0.50%-0.57%-0.70%-0.84%-0.86%-0.90%-1.41%-2.14%-6.75%-7.77%-4.01%
Return on Invested Capital (Quarter)
-32.51%3.03%1.75%0.96%0.99%0.75%0.48%1.82%4.49%2.16%1.47%-0.34%0.97%0.87%0.86%0.69%0.61%0.53%0.43%0.16%
Return on Assets (Quarter)
-0.56%-0.61%-0.63%-0.34%-0.26%-0.27%-0.24%-0.56%-0.46%-0.45%-0.49%0.00%-0.01%0.25%0.28%-0.43%-0.43%-1.06%-1.24%-0.04%
Return on Equity (Quarter)
-30.01%2.78%1.62%0.91%0.96%0.74%0.45%2.11%5.11%2.43%1.63%0.00%0.02%-0.35%-0.38%0.44%0.32%0.56%0.49%0.01%